Mario Boccadoro

TL;DR: In this phase I/II study, the efficacy and feasibility of MPTD in the setting of advanced myeloma patients are confirmed and interestingly a protective role of DF against thrombosis is also suggested.

TL;DR: A cross-sectional retrospective, prevalence-based study designed to measure resource utilization associated with MM management in terms of direct and indirect costs in a societal perspective finds that transplant and pharmacological treatments represent the most relevant costs, although counterbalanced by the highly increased clinical outcomes reported in the literature.

TL;DR: The role of allografting from unrelated donors in the treatment of myeloma was evaluated through a retrospective study through the Italian Bone Marrow Transplantation Donor Registry, with no difference in GVHD incidence among the 3 cohorts defined by type of conditioning.

TL;DR: Overall, refractory patients had a definitely short life expectancy, with a median survival of 21 months and a 14-yr survival projection of 10%, which is markedly worse compared to 88%, 76% and 65% survival projections at respectively 5, 10 and 15 yrs.